Abstract Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder, recently described in patients with advanced chronic kidney disease, usually after exposure to gadolinium (Gd)-based contrast agents, characterized by progressive fibrotic involvement mainly of the skin. At clinical examination, the cutaneous findings of NSF may partly resemble those of systemic sclerosis. However, the different topographic distribution of the skin thickening and hardening, usually involving the limbs and trunk, whilst sparing the face, the lack of serologic abnormalities and the distinctive histopathological findings allow this new disease entity to be distinguished from systemic sclerosis and other scleroderma-like fibrosing disorders (scleromyxedema, scleredema, eosinophilic fasciitis, etc.). Herein, we describe what, to best of our knowledge, is the first, biopsy proven, Italian case of NSF, which highlights the issue of the differential diagnosis between NSF and scleroderma-like fibrosing disorders.
Introduction
Nephrogenic systemic fibrosis (NSF) is a rare systemic fibrosing dermopathy, recently described in patients with advanced chronic kidney disease and characterized by progressive scleromyxedema-like fibrotic involvement not only of the skin, but also of internal organs (muscle, tendons, lungs, etc.), associated with significant morbidity and mortality [1] [2] [3] [4] [5] .
Initially described as an idiopathic cutaneous fibrosing disorder, presenting as symmetrical, wooden skin thickening with indurated papules and plaques on the limbs and trunk, this new disease entity seems to be pathophysiologically related to exposure to gadolinium (Gd)-based contrast agents (gadodiamide, then gadopentetate dimeglumine and gadoversetamide) during a contrast-enhanced magnetic resonance imaging [6] [7] [8] . According to this hypothesis, Gd deposits have recently been detected in the skin and soft tissue specimens of NSF patients, by scanning electron microscopy and spectroscopy [9, 10] . Then, a socalled ''cumulative risk factor model'' for NSF was proposed, where additional risk factors for NSF, in patients with renal failure, may be represented by: elevated parathyroid hormone (PTH) values, hypothyroidism, significant vascular disease, acidosis, hepatic disease, hypercoagulability (such as antiphospholipid antibody syndrome), proinflammatory events and/or infections [6, 11, 12] .
Although the cutaneous findings of NSF, at clinical examination, may mimic systemic sclerosis or other scleroderma-like fibrosing disorders (scleromyxedema, scleredema, eosinophilic fasciitis), the different topographic distribution of the skin thickening and hardening, the lack of serologic abnormalities and the distinctive histopathological findings allow for a differential diagnosis [13, 14] . This issue is highlighted in the case herein described, where a patient developed an unusual fibrosing dermopathy, resembling a scleromyxedema at the first examination that was later diagnosed as the first Italian, biopsy proven, case of NSF.
Case report
The case herein reported and more extensively detailed, from the nephrologic perspective, in our previous case report [15] , is a 66-year-old woman, on chronic haemodialysis for end-stage renal failure, also affected by the following comorbid diseases: arterial hypertension, hypokinetic myocardiopathy, occluding arteriopathy of the lower limbs, chronic obstructive bronchopneumopathy, severe hypothyroidism and secondary hyperparathyroidism and atopic diathesis to several medications. No Raynaud's phenomenon had been ever reported.
She was on a multi-drug pharmacological treatment, which included: angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist, acetylsalicylate, sevelamer, magnesium hydroxide, EPO, iron i.v. and cinacalcet.
In March 2007, 1 month after a contrast-enhanced magnetic resonance angiography with gadopentetate dimeglumine (Gd-DTPA, 40 ml), performed so as to evaluate occluding arteriopathy of the lower limbs, she began complaining of progressive, painful distal lower limb stiffness, which then spread symmetrically to the proximal segments of all four limbs. At clinical examination, a skin thickening and induration of the limbs and trunk (low back, thighs), sparing the face, was observed (Fig. 1) . The clinical picture worsened rapidly, inhibiting joint flexion and leading to gait disability, so that the patient became wheelchair-ridden. No telangiectasias, sclerodactyly, or digital pitting scars were detectable, but only small transient, erythematous, pruriginous dorsal skin lesions.
Laboratory examinations showed an increased PTH: 636 pg/ml (normal limits: 10-69 pg/ml), phosphorus: 8.3 mg/dl (2.7-4.5) and TSH: 150 lUI/ml (0.34-6); a decreased fT3: 2.3 pg/ml (1.8-4.2) and fT4: 0.29 ng/dl (0.8-1.9) and a slightly decreased C3 complement factor: 0.8 mg/dl (0.9-1.8). Neither immunological abnormalities nor autoantibody reactivity was detected; eosinophilia and monoclonal gammopathy were absent; ESR and CRP were normal, as were the plasma glucose concentrations.
A deep skin biopsy was taken from an affected area, revealing irregularly widespread, thickened collagen bundles with clefts, large collections of dermal mucins, abundant CD34 positive fibrocytes which, at times, extended into the subcutaneous tissue. Further examination by mass spectroscopy detected Gd deposits in the tissue. The patient died in April 2009.
Discussion
The case herein reported, in our opinion, supports the suggestion that NSF should be taken into account amongst the differential diagnoses in scleroderma-like disorders which are referred to rheumatologists. To this aim, clinical, serologic and, above all, histopathological features may allow NSF to be distinguished from other fibrosing dermopathies.
First, NSF should be suspected mainly in the clinical setting of advanced renal disease, whatever the aetiology, after exposure to Gd-based contrast agents, above all in the presence of metabolic, pharmacologic and/or inflammatory predisposing conditions, such as those (elevated PTH values, hypothyroidism, vascular disease, EPO therapy) shown by our patient.
As was the case with our patient, the clinical presentation of NSF may somewhat mimic the appearance of scleroderma. In fact, NSF is characterized by a symmetrical thickening and woody induration of the skin (sometimes accompanied by brownish or erythematosus, indurated plaques) in the distal parts of the limbs, which may extend to the proximal segments, involving the trunk, whilst, differently from scleroderma, the face is spared. Moreover, the serological and capillaroscopic abnormalities, typical of scleroderma, are usually lacking in NSF. However, as shown in our case, the skin biopsy plays a pivotal role in diagnosing NSF, as it is able to reveal the aforementioned distinctive histopathological features.
The cutaneous findings of NSF may also be misdiagnosed as scleromyxedema, a rare disorder, usually associated to monoclonal gammopathy, characterized by mucinous deposition in the skin; differently from NSF, the face is involved and perivascular inflammation is detected in skin biopsy.
Moreover, NSF may also mimic scleredema, another rare fibrosing dermopathy, which, unlike NSF, generally occurs in three clinical settings: poorly controlled diabetes, monoclonal gammopathies and infections, such as streptococcal pharyngitis, and involves the face, neck and back.
NSF may somewhat resemble the scleroderma-like skin changes of eosinophilic fasciitis, which may be differentiated on the basis of the typical association with remarkable peripheral eosinophilia, hypergammaglobulinaemia, increased ESR and histological evidence of fasciitis.
Finally, NSF may be differentiated from hypothyroidism (myxedema) by the absence of a pale, puffy face with oedematous eyelids, and by the histological features.
The case reported highlights the issue that NSF is an exclusion diagnosis in the context of the fibrosing dermopathies. When NSF is suspected, the skin biopsy plays a pivotal role, in order to reveal the distinctive histopathological findings and, possibly, the Gd deposits, as well as to prompt a highly relevant early differential diagnosis, both from a prognostic and therapeutical perspective.
